Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
A Trial of Ipatasertib in Combination With Atezolizumab

This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose

measurable disease
serum bilirubin
neutrophil count
cancer
platelet count
  • 15 views
  • 23 Jun, 2021
  • 1 location
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated unresectable

  • 0 views
  • 15 May, 2021
  • 17 locations
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with

bone metastases
trastuzumab
her2/neu-positive breast cancer
aptt
platelet count
  • 0 views
  • 25 Jan, 2021
  • 6 locations
Ipatasertib in Combination With Carboplatin Carboplatin/Paclitaxel or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

This phase I trial studies best dose of ipatasertib and how well it works with carboplatin with or without paclitaxel in treating patients with triple negative breast cancer that has spread to

  • 4 views
  • 25 Jan, 2021
  • 1 location
AKT Inhibitor Ipatasertib With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

This research is looking to find out if the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant can be an effective treatment for breast cancer.

estradiol
aromatase inhibitor
estrogen
measurable disease
erbb2
  • 6 views
  • 25 Jan, 2021
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

mammogram
advanced breast cancer
estrogen receptor
estrogen
aromatase inhibitor
  • 0 views
  • 23 Jun, 2021
  • 12 locations
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

> Patients with tumors positive for EBV or microsatellite instable tumors (30%) will be treated with atezolizumab and ipatasertib. Patients with genomically stable tumors (20

  • 0 views
  • 06 Apr, 2021
  • 8 locations